![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.001.102 |
Chemical and physical data | |
Formula | C10H21N |
Molar mass | 155.285 g·mol−1 |
3D model (JSmol) | |
|
Pempidine is a ganglion-blocking drug, first reported in 1958 by two research groups working independently, and introduced as an oral treatment for hypertension. [1]
Reports on the "classical" pharmacology of pempidine have been published. [2] [3] The Spinks group, at ICI, compared pempidine, its N-ethyl analogue, and mecamylamine in considerable detail, with additional data related to several structurally simpler compounds. [2]
LD50 for the HCl salt of pempidine in mice: 74 mg/kg (intravenous); 125 mg/kg (intraperitoneal); 413 mg/kg (oral). [2]
Pempidine is an aliphatic, sterically hindered, cyclic, tertiary amine, which is a weak base: in its protonated form it has a pKa of 11.25. [4]
Pempidine is a liquid with a boiling point of 187–188 °C and a density of 0.858 g/cm3. [2]
Two early syntheses of this compound are those of Leonard and Hauck, [5] and Hall. [4] These are very similar in principle: Leonard and Hauck reacted phorone with ammonia, to produce 2,2,6,6-tetramethyl-4-piperidone, which was then reduced by means of the Wolff–Kishner reduction to 2,2,6,6-tetramethylpiperidine. This secondary amine was then N-methylated using methyl iodide and potassium carbonate. [6]
Hall's method involved reacting acetone with ammonia in the presence of calcium chloride to give 2,2,6,6-tetramethyl-4-piperidone, which was then reduced under Wolff–Kishner conditions, followed by N-methylation of the resulting 2,2,6,6-tetramethylpiperidine with methyl p-toluenesulfonate.